Literature DB >> 28533307

SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.

Patricia Balsas1,2, Jara Palomero1, Álvaro Eguileor1,2, Marta Leonor Rodríguez1, Maria Carmela Vegliante1, Ester Planas-Rigol1,3, Marta Sureda-Gómez1, Maria C Cid1,3, Elias Campo1,2,4, Virginia Amador1,2.   

Abstract

SOX11 overexpression in mantle cell lymphoma (MCL) has been associated with more aggressive behavior and worse outcome. However, SOX11 oncogenic pathways driving MCL tumor progression are poorly understood. Here, we demonstrate that SOX11 binds to regulatory regions of 2 important genes for microenvironment signals in cancer: (C-X-C motif) chemokine receptor 4 (CXCR4) and PTK2 (encoding for focal adhesion kinase [FAK]). Moreover, SOX11+ xenograft and human primary MCL tumors overexpress cell migration and stromal stimulation gene signatures compared with their SOX11- counterparts. We show that SOX11 directly upregulates CXCR4 and FAK expression, activating PI3K/AKT and ERK1/2 FAK-downstream pathways in MCL. Concordantly, SOX11+ MCL cells have higher cell migration, transmigration through endothelial cells, adhesion to stromal cells, and cell proliferation and display an increased resistance to conventional drug therapies compared with SOX11- MCL cells. Specific FAK inhibition blocks downstream PI3K/AKT- and ERK1/2-mediated phosphorylation. Additionally, specific FAK and PI3K inhibitors reduce SOX11-enhanced MCL cell migration and stromal interactions and revert cell adhesion-mediated drug resistance (CAM-DR) to the same levels as SOX11- MCL cells. In intravenous MCL xenograft models, SOX11+ MCL cells display higher cell migration, invasion, and growth compared with SOX11-knockdown cells, and specific FAK and CXCR4 inhibitors impair SOX11-enhanced MCL engraftment in bone marrow. Overall, our results suggest that SOX11 promotes MCL homing and invasion and increases CAM-DR through the direct regulation of CXCR4 and FAK expression and FAK/PI3K/AKT pathway activation, contributing to a more aggressive phenotype. Inhibition of this pathway may represent an efficient strategy to overcome stromal-mediated chemotherapy refractoriness in aggressive MCL.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28533307     DOI: 10.1182/blood-2017-04-776740

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Silencing of LIMD1 promotes proliferation and reverses cell adhesion-mediated drug resistance in non-Hodgkin's lymphoma.

Authors:  Jie Tang; Liqun Zhu; Yuejiao Huang; Bing Shi; Shuqing Zhang; Lingli Gu; Jie Zhao; Minghao Deng; Jiahao Zhu; He Xun; Yuchan Wang; Chun Wang
Journal:  Oncol Lett       Date:  2019-01-11       Impact factor: 2.967

Review 2.  Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.

Authors:  Khalil Saleh; Morgane Cheminant; David Chiron; Barbara Burroni; Vincent Ribrag; Clémentine Sarkozy
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 3.  Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.

Authors:  Michael R Cook; Kieron Dunleavy
Journal:  Curr Oncol Rep       Date:  2022-04-11       Impact factor: 5.945

Review 4.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

5.  MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.

Authors:  Baoyu Wu; Jingyu Li; Han Wang; Qian Wu; Hui Liu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-02-10       Impact factor: 3.000

6.  Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.

Authors:  Atish Mohanty; Natalie Sandoval; An Phan; Thang V Nguyen; Robert W Chen; Elizabeth Budde; Matthew Mei; Leslie Popplewell; Lan V Pham; Larry W Kwak; Dennis D Weisenburger; Steven T Rosen; Wing C Chan; Markus Müschen; Vu N Ngo
Journal:  Blood       Date:  2018-12-10       Impact factor: 25.476

7.  SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.

Authors:  Patricia Balsas; Luis Veloza; Guillem Clot; Marta Sureda-Gómez; Marta-Leonor Rodríguez; Christos Masaoutis; Gerard Frigola; Alba Navarro; Silvia Beà; Ferran Nadeu; Eva Giné; Armando López-Guillermo; Antonio Martínez; Inmaculada Ribera-Cortada; Pablo Engel; Leticia Quintanilla-Martínez; Wolfram Klapper; Elias Campo; Virginia Amador
Journal:  Blood       Date:  2021-12-02       Impact factor: 22.113

Review 8.  The pathologic diagnosis of mantle cell lymphoma.

Authors:  Shaoying Li; Jie Xu; M James You
Journal:  Histol Histopathol       Date:  2021-06-11       Impact factor: 2.303

Review 9.  CAM-DR: Mechanisms, Roles and Clinical Application in Tumors.

Authors:  Yuejiao Huang; Yuchan Wang; Jie Tang; Shiyi Qin; Xianjuan Shen; Song He; Shaoqing Ju
Journal:  Front Cell Dev Biol       Date:  2021-07-06

Review 10.  Progress in molecular feature of smoldering mantle cell lymphoma.

Authors:  Panruo Jiang; Aakash Desai; Haige Ye
Journal:  Exp Hematol Oncol       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.